Avis Budget Group Inc (CAR) Stock News

Rosen Law Firm has filed a class action lawsuit against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group securities. The defendants allegedly used their position as a major shareholder (holding ~51% economic interest) to aggressively purchase Avis stock during February 2025 to April 2026, triggering a short squeeze and artificial price volatility that benefited their holdings. Investors who purchased Avis securities during this period may be eligible for compensation.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

Bernstein Liebhard LLP has filed securities class action lawsuits against Avis Budget Group for allegedly orchestrating a market manipulation scheme involving short squeezes, and is investigating potential breaches of fiduciary duty at Capricor Therapeutics and Calix. Investors who suffered losses during the specified periods are encouraged to participate in the class actions.

A securities fraud class action lawsuit has been filed against AeroVironment (NASDAQ:AVAV) after its stock plummeted 17% following the U.S. Space Force's cancellation of its SCAR contract for BADGER antenna systems. The company allegedly misled investors about the contract's status and likelihood of competition. AeroVironment also announced a $151.3 million goodwill impairment related to the BlueHalo acquisition and restated financial statements.

Bernstein Liebhard LLP, an investor rights law firm, is investigating whether certain directors and officers of CarMax, Inc. breached fiduciary duties owed to the company. The firm is seeking shareholders who purchased shares prior to June 20, 2025, to discuss their legal rights and options.

BBG Advanced Therapies, a subsidiary of BioBridge Global, has partnered with Kite (a Gilead Company) to deploy a Mobile Leukapheresis Center across Texas. This first-of-its-kind platform brings T-cell collection directly to patients' communities, reducing travel burdens and expanding access to Kite's CAR T-cell therapies for blood cancer treatment. The initiative addresses the gap where only 2 in 10 eligible U.S. patients currently receive these treatments.

Amerant Investments announced the appointment of Ricardo Sucre as Head of International Wealth Management Business Development. Sucre brings over 20 years of experience from leading financial institutions including Morgan Stanley and Bolton Global Capital. The appointment reflects Amerant's strategic focus on expanding its international wealth management platform and attracting experienced financial advisors to its integrated banking and investment services model.

Carbios held its Annual General Assembly on June 18, 2026, with 27.72% shareholder participation and all resolutions approved with over 87% favorable votes. The company announced the creation of Kaibio Biotechnology Co. Ltd, a joint venture with Wankai to build and operate China's first PET biorecycling plant under Carbios' technology license. The board was reconstituted with eight administrators, four of whom are independent.

Carbios held its Annual General Meeting on June 18, 2026, with all resolutions approved by over 87% of shareholders. The company announced the creation of a joint venture with Wankai called Kaibio Biotechnology Co. Ltd to build and operate the first PET biorecycling plant in China under a licensing agreement. Carbios retains full ownership of its patents while granting Wankai usage rights to its enzymatic recycling technology.

Epson Robots, the world's #1 SCARA robot manufacturer, will showcase its automation portfolio at Automate 2026 (June 22-25 in Chicago), including SafeSense technology, SCARA and 6-Axis robots, and a preview of its upcoming collaborative robot platform planned for 2026. The company will feature interactive demonstrations, speaking engagements, and software solutions designed to help manufacturers automate quickly and cost-effectively.

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.

InspireMD announced the first patient enrollment in the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system used with CGuard Prime 80 cm stent in TCAR procedures. The prospective, multi-center study will enroll approximately 103 subjects to evaluate safety and efficacy for treating carotid artery stenosis. The company projects 70,000 TCAR procedures annually in the U.S. by 2030.

DIAGNOS announced a flash report highlighting progress toward regulatory approvals for its CARA AI platform from Health Canada, FDA, and SFDA. The company has assessed over 400,000 patients across 140 clinics and maintains partnerships with major optical industry players. An independent market study projects the global AI-powered retinal image analysis market could grow from US$2.65 billion in 2023 to US$9.4 billion by 2033.

DIAGNOS announced that Emerging Growth Research published a flash report highlighting the company's progress toward key regulatory approvals for its CARA AI platform. The company is pursuing regulatory authorizations from Health Canada, FDA, and Saudi FDA, with a Health Canada submission targeted for June 10, 2026. CARA has evaluated over 400,000 patients across 140 clinics in 16 countries and detects early signs of age-related macular degeneration and diabetic retinopathy. The addressable market opportunity is estimated at approximately CAD 11 billion.

Immix Biopharma reported a 95% complete response rate (19 of 20 patients) in its NEXICART-2 Phase 2 trial for relapsed/refractory AL Amyloidosis using its CAR-T therapy NXC-201. All four MRD-negative patients from ASH 2025 converted to complete response, with no relapses observed to date. The company plans to initiate a Phase 3 trial in newly diagnosed patients and expects BLA submission by end of March 2027.

LONDON , May 19, 2026 /PRNewswire/ -- ECARX Holdings Inc. (NASDAQ: ECX ) ("ECARX" or the "Company"), a leading global automotive intelligence company, today announced unaudited financial results for the quarter ended March 31, 2026. Ziyu Shen, ECARX CEO, commented, "The first quarter of 2026 was defined by continued disciplined execution and continued global momentum, demonstrating the underlying resilience of our core business. Despite traditional seasonality and a complex macroeconomic environment marked by memory component inflation, our disciplined execution mitigated the modest impact on our topline into meaningful profitability improvements. We successfully expanded our gross margin to 21.4% and nearly halved our operating loss from the same period last year. Perhaps most notably, we achieved our third consecutive quarter of positive adjusted EBITDA at US$4 million. This resilient performance is the direct result of the strategic framework we established late last year where our focus remains firmly on accelerating our globalization strategy, investing in our R&D roadmap, and optimizing our lean operating strategy to sustain profitability. R&D costs were down 32% YoY, driven by continued resource prioritization and the internal deployment of AI across our business to drive innovation while reducing structural costs. We are rapidly accelerating our transformation into a truly global technology leader. To support our expanding commercial footprint and align with global best practices, we have recently actively strengthened our corporate governance and leadership team, separating the roles of Chairperson and CEO and welcoming Lone Fønss Schrøder to lead our Board of Directors, alongside Dylan D. Jeng as our new Chief Financial Officer. With our offices in Singapore now fully operational, and the capital raised late last year actively being deployed, we are

Law firm Bragar Eagel & Squire is investigating GE HealthCare Technologies for potential securities law violations following the company's April 29, 2026 earnings announcement. GE HealthCare missed Q1 2026 consensus EPS estimates ($0.99 vs. $1.05 expected) and reduced full-year guidance to $4.80-$5.00 from $4.95-$5.15, citing a PDx supplier issue. The stock declined 13% ($9.01 per share) on the news.

Buscar Company (CGLD) announced significant progress in permitting for its Treasure Canyon Gold Mine project in Plumas County, California. The company has received multiple approvals including a burn permit from the Northern Sierra Air Quality Management District and a Lake and Streambed Alteration Agreement from the California Department of Fish and Wildlife. The project continues advancing through federal and state regulatory reviews with ongoing coordination among agencies.